BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

...requiring continuous positive airway pressure (four patients) or intubation (two patients) received the mAb against MASP2...
...IL-8 (CXCL8) - Interleukin-8 IL-17A - Interleukin-17A IL-17F - Interleukin-17F LDH - Lactate dehydrogenase MASP2 -Mannan binding lectin serine peptidase 2...
...growth factor Danielle Golovin Veklury, remdesivir (GS-5734) Narsoplimab (OMS721) PTC299 Gilead Sciences Inc. Omeros Corp. PTC Therapeutics Inc. International AIDS Vaccine Initiative (IAVI) Wellcome Trust Mannan binding lectin serine peptidase 2 (MASP2) Interleukin-6...
BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

...that the nucleocapsid (N) proteins of SARS-CoV-2, SARS and MERS-CoV all bound the complement activator MASP2...
...proteins also potentiated lipopolysaccharide (LPS)-induced pneumonia in mice. Targets C5a - Complement 5a MASP2 - Mannan binding lectin serine peptidase 2 (MASP2) Sandi...
BioCentury | Dec 4, 2019
Clinical News

Omeros’ narsoplimab headed for 1H20 submission on back of readout

...For the patients who received at least four weeks of dosing of the mAb against mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Oct 5, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

...company plans to present additional data at a medical meeting. OMS721, a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
...Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Renal Molecular target: Mannan binding lectin serine peptidase 2 (MASP2) Description: Human mAb against MASP2...
...Endpoint: Safety; change from baseline in proteinuria Status: Phase II data Milestone: NA Jaime De Leon OMS721 Omeros Corp. Mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Oct 2, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II

...company plans to present additional data at a medical meeting. OMS721, a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
...to treat atypical hemolytic uremic syndrome and hematopoietic stem cell transplant-associated thrombotic microangiopathy. Jaime De Leon OMS721 Omeros Corp. Mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Aug 3, 2018
Politics & Policy

ICER announces preliminary 2019 topics

...Celgene that is in Phase I/II testing for DLBCL. OMS721 is a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Aug 2, 2018
Company News

Management tracks: Omeros, EdiGene

...from J. Steven Whitaker, who will now lead development of OMS721. The human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Mar 16, 2018
Clinical News

Omeros reports Phase II OS data for OMS721 in thrombotic microangiopathy

...activity as measured by platelet count, pharmacokinetics and immunogenicity. OMS721 is a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
...Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Hematology Molecular target: Mannan binding lectin serine peptidase 2 (MASP2) Description: Human mAb against MASP2...
...measured by platelet count; pharmacokinetics and immunogenicity Status: Phase II data Milestone: NA Elizabeth S. Eaton OMS721 Omeros Corp. Mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Jan 5, 2018
Clinical News

Omeros to start Phase III trial of OMS721 to treat IgA nephropathy

...size for the eGFR endpoint also will be adjustable. OMS721 is a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
...Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Renal Molecular target: Mannan binding lectin serine peptidase 2 (MASP2) Description: Human mAb against MASP2...
...at 24 weeks; estimated glomerular filtration rate Status: Phase III start Milestone: NA Jaime De Leon OMS721 Omeros Corp. Mannan binding lectin serine peptidase 2 (MASP2)...
BioCentury | Nov 10, 2017
Company News

Omeros soars on single Phase III plan for OMS721

...completion date after it finalizes the study design with FDA. OMS721, a human mAb against mannan binding lectin serine peptidase 2 (MASP2)...
...in a follow-on (see BioCentury Extra, Aug. 15) . Jaime De Leon ketorolac/phenylephrine Omidria OMS302 OMS721 Omeros Corp. Adrenergic receptor alpha 1 (ADRA1) Cyclooxygenases Mannan binding lectin serine peptidase 2 (MASP2)...
Items per page:
1 - 10 of 30